$THC

Foo Lisa Y sold $2.6M of THC

Foo Lisa Y (EVP, Chief Operating Officer) sold 10,000 shares of TENET HEALTHCARE CORP (THC) at $258.03 ($2.58M total) on 2026-07-29.

Original reporting
SEC EDGAR · Foo Lisa Y
Published Aug 1, 2026, 12:00 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 1, 2026, 12:03 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$THC
Neutral
medium confidence
Mentioned
$THC
Relevance
6/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$THCNeutralLow
01

Why it matters

The newest fact is the specific sale details: 10,000 shares at $258.03, total value $2.58M, with holdings after sale of 32,053 shares, and no pre-arranged 10b5-1 plan.

02

Market read

Traders may note the insider sale, but there is no accompanying fundamental catalyst in the text.

03

What to watch

Insider sales can be driven by diversification, tax planning, or pre-existing personal liquidity needs; without additional context, the signal-to-noise is low.

Relevance 6/10Novelty 4/10Timing: Form 4 filed 2026-07-31, transaction dated 2026-07-29

Background

The article is an SEC Form 4 insider transaction disclosure for Tenet Healthcare, reporting an open-market sale by the COO.

Company-level read

Ticker impact

$THCNeutralMedium confidence
Context

Tenet Healthcare COO sold 10,000 shares in an open-market transaction at $258.03 on 2026-07-29, per Form 4 filed 2026-07-31.

Expected impact

Likely limited near-term impact; treat as low-signal unless paired with other disclosures or unusual volume.

Evidence & confidence

The filing discloses transaction size, price, and holdings, but provides no earnings, guidance, investigation, or deal catalyst. Insider sales are common and often non-informational, though the absence of a 10b5-1 plan slightly increases interpretive uncertainty.

Market effects

No clear sector read-through from a single insider sale at one healthcare services company.

None indicated.

None indicated.

Counterpoint

The lack of a 10b5-1 plan could reflect discretionary selling ahead of perceived risk, so some traders may front-run downside if they treat insider behavior as a leading indicator.

Key entities

  • Tenet Healthcare Corp

    Subject of the Form 4 insider transaction disclosure.

  • Foo Lisa Y

    EVP, Chief Operating Officer who sold shares.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$THCMed

Tenet Healthcare (THC) Refinances Debt On A Fair Value Story That Looks Tightly Priced

Tenet Healthcare (THC) issued $2b in 6.250% senior notes due 2034 to refinance existing debt. Its share price has risen 25.4% in 90 days and 29.7% year-to-date. The company's fair value is estimated at $260, slightly above its current price of $258.62. Management's cost-reduction efforts have lowered contract labor and certain analytics costs, but further margin expansion may be limited.

$THCMed

Can THC's Cash Flow Support Its Expanding Capital-Return Strategy?

Tenet Healthcare (THC) reported a 27.1% year-over-year increase in operating cash flow to $2.2B in H1 2026, raising its adjusted free cash flow guidance to $1.825B-$2.055B. The company spent $1.4B on share buybacks and increased its repurchase authorization by $2B. THC is balancing buybacks with growth investments, expecting $700M-$800M in capital spending. Peers UHS and HCA also reported significant buybacks and capital investments.

$THCMed

Is Tenet Healthcare Corporation (THC) A Solid Play on Expanding Ambulatory Business?

Tenet Healthcare (THC) is focusing on its ambulatory business for growth, with BMO Capital Markets noting favorable long-term trends and margins. USPI, Tenet’s ambulatory platform, reported 9.3% revenue growth in Q2. BMO initiated coverage with a Market Perform rating and $265 price target. Hedge funds increased stakes, while short interest declined. Risks include reimbursement changes and competition.

$THCMedAI 8/10

What Tenet Healthcare (THC)'s $2 Billion Debt Refinance Means For Shareholders

Tenet Healthcare (THC) completed a $2 billion private placement of senior unsecured notes due 2034 at a 6.250% coupon. Proceeds will redeem $1.5 billion of 2027 secured notes and $0.5 billion of 2028 senior notes, altering its capital structure and interest obligations. Analysts project revenues of $24.1 billion and earnings of $1.6 billion by 2029, with some seeing potential upside.

$THCMedAI 8/10

What Tenet Healthcare (THC)'s $2b Debt Refinance Means For Shareholders

Tenet Healthcare (THC) priced a $2.0 billion private placement of 6.250% senior notes due 2034, upsized from $1.5 billion, to refinance existing 2027 and 2028 debt. The refinancing replaces secured and partly secured borrowings with unsecured notes, altering the company's debt structure. Investors focus on execution, pricing, and free cash flow, with high debt and earnings declines noted as risks.